graph Evidence gap map comparisons
camrelizumab based treatmentnivolumab based treatmentpembrolizumab based treatment
camrelizumab alone nivolumab alone pembrolizumab alone
mEC - 2nd line (L2) 3       
Comparator:  vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;